16-week Flexible vs. 8-week Semaglutide Titration

NCT04447859 on ClinicalTrials.gov · last registry update 2020-06-25

A small phase 3 — 100 participants, against a typical 424. Its estimated completion date, 10 May 2022, has passed with no update to the record. Primary outcome, as filed: Gastrointestinal adverse events (GI-AEs). A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here.

Status: UNKNOWN
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Tel-Aviv Sourasky Medical Center
Sponsor type: Other Gov
Enrollment: 100
Started: 2020-02-23
Primary completion: 2022-05-10 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Gastrointestinal adverse events (GI-AEs)

Conditions studied

Diabetes type2

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.